Welcome to the Rethinking Schools Archives and Website

Become a subscriber or online account holder to read this article and hundreds more. Learn more.

Already a subscriber or account holder? Log in here.


Preview of Article:

Diseases Laud Kansas Decision

The Ebola Virus, speaking from its headquarters somewhere in Africa, today thanked the Kansas Board of Education for its recent decision to remove evolution from the state's science curriculum. The virus pointed out that the resulting eventual loss of evolutionary biologists would make life easier for it and many other emerging diseases, as health workers would not be able to distinguish between lethal and nonlethal strains that had evolved from one to the other.

In its two recent visits to the United States, the Ebola strains involved were those that had evolved from deadly human strains into strains that kill monkeys, not people. "If they hadn't known, we could really have inspired hysteria," commented Ebola. "More fun next time."

Meanwhile, Hantavirus, Cholera, AIDS, and Influenza announced that they had no intention of stopping their own evolution and looked forward to even more successful world tours in the future. Although none of them expressed much interest in visiting Kansas, they denied they had plans to boycott the state.

Finally, stock futures for a variety of "old-fashioned" diseases (such as diphtheria, streptococcus, malaria, and tuberculosis) went up, as it appears that humans now are increasingly prepared to ignore the evolution of antibiotic resistance for diseases that have long been held in check by modern medicines.

Diphtheria, speaking from its exile in poorer parts of the former U.S.S.R. commented, "The lack of new antibiotics seems to reflect a human arrogance that assumes we can't evolve and come back." It pointed out that malaria and TB had already evolved forms that were immune to all known antibiotics. "Without understanding how we evolve, humans are turning themselves into fodder."

To Read the Rest of This Article:

Become a subscriber or online account holder to read this article and hundreds more. Learn more.

Already a subscriber or account holder? Log in here.